Actimed Therapeutics Limited - Accounts to registrar (filleted) - small 18.2

REGISTERED NUMBER: 10519588 (England and Wales)

Unaudited Financial Statements

for the Period

9 December 2016 to 31 March 2018

for

Actimed Therapeutics Limited

Page

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3

DIRECTORS:

AJS Coats

GR Parkin

DR Ebsworth

FJP Misselwitz

SECRETARY:

H Jackson

REGISTERED OFFICE:

The Old Bakehouse

Course Road

Ascot

Berkshire

SL5 7HL

REGISTERED NUMBER:

10519588 (England and Wales)

ACCOUNTANTS:

Jacksons Accountants (Ascot) Limited

The Old Bakehouse

Course Road

Ascot

Berkshire

SL5 7HL

FIXED ASSETS

Intangible assets

4

195,615

CURRENT ASSETS

Debtors

5

19,201

Cash at bank

237,961

257,162

CREDITORS

Amounts falling due within one year

6

195,881

NET CURRENT ASSETS

61,281

TOTAL ASSETS LESS CURRENT LIABILITIES

256,896

CAPITAL AND RESERVES

Called up share capital

933

Share premium

370,526

Retained earnings

(114,563

)

256,896

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2018.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2018 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a)	ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b)

preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors on 27 June 2018 and were signed on its behalf by:

GR Parkin - Director

1.	STATUTORY INFORMATION

Actimed Therapeutics Limited is a private company, limited by shares , registered in England and Wales. The

company's registered number and registered office address can be found on the Company Information page.

2.	ACCOUNTING POLICIES

Basis of preparing the financial statements

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Intangible assets

Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost

less any accumulated amortisation and any accumulated impairment losses.

Patents are being amortised evenly over their estimated useful life of ten years.

Taxation

Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to

the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or

substantively enacted by the balance sheet date.

Deferred tax

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance

sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from

those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that

have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the

timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they

will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Research and development costs

Capitalisation of expenditure on product development commences from the point at which technical feasibility

and commercial viability of the product can be demonstrated and the company is satisfied that it is probable that

future economic benefits will result from the product once completed. No such costs have been capitalised to

date, given the early stage of the company's product development

Expenditure on research and development activities that do not meet the above criteria is charged to the Income

Statement as incurred.

3.	EMPLOYEES AND DIRECTORS

The average number of employees during the period was 2 .

4.	INTANGIBLE FIXED ASSETS

Other

intangible

assets

£

COST

Additions

195,615

At 31 March 2018

195,615

NET BOOK VALUE

At 31 March 2018

195,615

5.

DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Other debtors

19,201

6.

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

£

Trade creditors

94,882

Taxation and social security

4,387

Other creditors

96,612

195,881